Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
We break down expense ratios across popular index funds and show how choosing the lowest-cost options can improve long-term retirement outcomes.
28,023 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
A potential U.S. strike on Iran could squeeze global oil supplies and push prices higher, forcing households and inve...
Fluence Energy’s stock surged after-hours on news of two hyperscaler storage deals, even as Q2 revenue disappointed. ...
Susquehanna lifts Baidu's price target to $140 while maintaining a Neutral rating, citing AI Cloud strength but ongoi...
Healthcare fraud hits your wallet. This piece explains a real case where a lab owner allegedly billed Medicaid for te...
Tech’s latest earnings show Big Tech leaning into AI infrastructure, pushing capital spending higher as data centers ...
Institutions are back in force for Bitcoin, led by US Bitcoin ETFs and MicroStrategy buying. Flows total about $1.25B...
When a senior executive at Maze Therapeutics sells a stake after positive trial data and solid quarterly results, inv...
NextEra Energy is set to buy Dominion Energy in a $67 billion all-stock deal aimed at securing power capacity for AI-...
A major AI and cloud deal is flanking SpaceX's IPO, potentially nudging investor sentiment. This article breaks down ...
Looking for a single artificial intelligence stock hold to ride AI-era gains for 10 years? This guide explains why Al...
The housing market is a split landscape in March 2026: some areas surge with demand while others cool after sharp cor...